Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The Effect of a Cellular-Enabled Glucose Meter on Glucose Control for Patients With Diabetes: Prospective Pre-Post Study.

Bollyky JB, Melton ST, Xu T, Painter SL, Knox B.

JMIR Diabetes. 2019 Oct 7;4(4):e14799. doi: 10.2196/14799.

2.

Reduced medical spending associated with increased use of a remote diabetes management program and lower mean blood glucose values.

Whaley CM, Bollyky JB, Lu W, Painter S, Schneider J, Zhao Z, He X, Johnson J, Meadows ES.

J Med Econ. 2019 Sep;22(9):869-877. doi: 10.1080/13696998.2019.1609483. Epub 2019 May 8.

PMID:
31012392
3.

Remote Lifestyle Coaching Plus a Connected Glucose Meter with Certified Diabetes Educator Support Improves Glucose and Weight Loss for People with Type 2 Diabetes.

Bollyky JB, Bravata D, Yang J, Williamson M, Schneider J.

J Diabetes Res. 2018 May 16;2018:3961730. doi: 10.1155/2018/3961730. eCollection 2018.

4.

Elimination diet and the development of multiple tree-nut allergies.

Elizur A, Bollyky JB, Block WM.

Pediatr Res. 2017 Oct;82(4):671-677. doi: 10.1038/pr.2017.127. Epub 2017 Jun 14.

PMID:
28549059
5.

Association of Clinical Reactivity with Sensitization to Allergen Components in Multifood-Allergic Children.

Andorf S, Borres MP, Block W, Tupa D, Bollyky JB, Sampath V, Elizur A, Lidholm J, Jones JE, Galli SJ, Chinthrajah RS, Nadeau KC.

J Allergy Clin Immunol Pract. 2017 Sep - Oct;5(5):1325-1334.e4. doi: 10.1016/j.jaip.2017.01.016. Epub 2017 Mar 27.

6.

4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer.

Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, Bollyky PL.

Front Immunol. 2015 Mar 23;6:123. doi: 10.3389/fimmu.2015.00123. eCollection 2015. Review.

7.

Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective.

Bollyky JB, Xu P, Butte AJ, Wilson DM, Beam CA, Greenbaum CJ; Type 1 Diabetes TrialNet Study Group.

Diabetes Metab Res Rev. 2015 Sep;31(6):588-94. doi: 10.1002/dmrr.2643. Epub 2015 Apr 23.

8.

Evaluation of in vivo T cell kinetics: use of heavy isotope labelling in type 1 diabetes.

Bollyky JB, Long SA, Fitch M, Bollyky PL, Rieck M, Rogers R, Samuels PL, Sanda S, Buckner JH, Hellerstein MK, Greenbaum CJ.

Clin Exp Immunol. 2013 Jun;172(3):363-74. doi: 10.1111/cei.12064.

9.

The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation.

Bollyky PL, Bogdani M, Bollyky JB, Hull RL, Wight TN.

Curr Diab Rep. 2012 Oct;12(5):471-80. doi: 10.1007/s11892-012-0297-0. Review.

10.

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.

Long SA, Rieck M, Sanda S, Bollyky JB, Samuels PL, Goland R, Ahmann A, Rabinovitch A, Aggarwal S, Phippard D, Turka LA, Ehlers MR, Bianchine PJ, Boyle KD, Adah SA, Bluestone JA, Buckner JH, Greenbaum CJ; Diabetes TrialNet and the Immune Tolerance Network.

Diabetes. 2012 Sep;61(9):2340-8. doi: 10.2337/db12-0049. Epub 2012 Jun 20.

Supplemental Content

Loading ...
Support Center